Removal of gadolinium by dialysis: Review of different strategies and techniques

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 6, 2009, Pages 1347-1349

  Silberzweig, Jeffrey I ^a,b   Chung, Miriam ^a,b  

^a ROGOSIN INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chronic kidney disease; Dialysis; Gadolinium; Nephrogenic systemic fibrosis

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; CREATININE; GADODIAMIDE; GADOLINIUM CHELATE; IRON; PARATHYROID HORMONE; PHOSPHORUS; UREA;

BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTRAST INDUCED NEPHROPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY GRAFT; KIDNEY INJURY; METABOLIC ACIDOSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; THROMBOSIS; TOXICITY; VASCULAR SURGERY;

CONTRAST MEDIA; DIALYSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 73649147753     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21981     Document Type: Conference Paper

References (31)

1. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-906.
2. Kucher C, Steere J, Elenitsas R, Siegel DC, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006;54:S31-S34.
3. Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7:237-247.
4. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000;356:1000-1001.
5. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008;5:45-52.
6. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
7. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
8. Deo A, Fogel M, Cowper SE. Neprhrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-267.
9. Steen H, Giannitsis E, Sommerer C, et al. Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant 2009;24:1274-1277.
10. Schieren G, Tokmak F, Lefringhausen L, et al. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. Am J Kidney Dis 2008;51:976-986.
11. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: A critical review. Toxicology 2008;248:77-88.
12. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-816.
13. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 2008;17:315-319.
14. Canavese C, Mereu MC, Aime S, et al. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J Nephrol 2008;221:324-336.
15. Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008;21:135-139.
16. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18:2636-2643.
17. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-975.
18. Cowper SE. Nephrogenic fibrosing dermopathy: the first six years. Curr Opin Rheum 2003;15:785-790.
19. Nainani N, Panesar M. Nephrogenic systemic fibrosis. Am J Nephrol 2009;29:1-9.
20. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008;66:175-179.
21. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
22. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Ominscan) versus Gd (HP-Do3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
23. Perazella MA. Nephrogenic systemic fibrosis, kidney disease and gadolinium: is there a link? Clin J Am Soc Nephrol 2007;2:200-202.
24. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
25. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura, Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006;24:445-451.
26. Murashima M, Drott HR, Carlow D, et al. Removal of gadolinium by peritoneal dialysis. Clin Nephrol 2008;69:368-372.
27. Choyke PL, Girton ME, Vaughan EM, Frank JA, Austin, HA. Clearance of gadolinium by hemodialysis: an in vitro study. J Magn Reson Imaging 2008;5:470-472.
28. Yerram PL, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007;2:258-263.
29. Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant 2008;23:3280-3282.
30. Knopp EA. Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-128.
31. Pieringer H, Schemkal B, Janko O, Biesenbach, G. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3094.